Granutec fails to "appropriately" investigate metal contamination in manufacturing -- FDA.
This article was originally published in The Tan Sheet
Executive Summary
GRANUTEC FAILURE TO "APPROPRIATELY" INVESTIGATE METAL CONTAMINATION in its OTC drug manufacturing processes was cited by FDA in a Jan. 31 warning letter to the firm. The warning letter followed an inspection of the company's manufacturing plant between Dec. 21, 1994 and Jan. 9, 1995. The inspection was conducted as a follow-up to the company's recent acetaminophen recalls due to the presence of metal particles. Based in Wilson, N.C., Granutec manufactures private-label OTC analgesics and cold medications.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning